Follow-up study of two phase II trials of capecitabine plus oxaliplatin (CapeOX) or S-1 plus oxaliplatin (SOX) as adjuvant therapy after curative resection of gastric cancer.

Follow-up study of two phase II trials of capecitabine plus oxaliplatin (CapeOX) or S-1 plus oxaliplatin (SOX) as adjuvant therapy after curative resection of gastric cancer. - Follow-up study of two phase II trials of capecitabine plus oxaliplatin (CapeOX) or S-1 plus oxaliplatin (SOX) as adjuvant therapy after curative resection of gastric cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026883

Enrollment

162

Registered

2017-04-10

Start date

2017-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients in full set analysis of J-CLASSIC-PII or SOXaGC trial

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Disease free survival Overall survival	—

Countries

Japan

Contacts

Public ContactYoshiaki Nakamura

National Cancer Center Hospital East Department of Gastrointestinal Oncology

yoshinak@east.ncc.go.jp04-7133-1111

Outcome results